Algernon Pharmaceuticals Selects NP-120 (Ifenprodil) for its Lead Phase 2 Trial for Idiopathic Pulmonary Fibrosis and Chronic Cough Pharmaceutical Investing
Life Science Big News Roundup: Algernon’s NP-120 Outperforms Merck’s Phase 3 Drug MK-7264 by 110 Percent; Naturally Splendid’s Natera Sport(TM) Bites at Genesis PGA Tournament Life Science Investing
FSD Pharma to Present at 12th Annual LD Micro Main Event Investor Conference on December 11 Cannabis Investing News
Algernon Pharmaceuticals’ NP-120 (Ifenprodil) Outperforms Merck’s Phase 3 Drug MK-7264 (Gefapixant) in an Acute Cough Study by 110 Percent Biotech Investing
BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer
